HPC
STOK icon

HM Payson & Co’s Stoke Therapeutics STOK Stock Holding History

HM Payson & Co’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-99
Closed -$2K – 1151
2021
Q4 		$2K Buy
+99
New +$2.36K ﹤0.01% 1021
2021
Q2 		– Sell
-218
Closed -$8K – 1171
2021
Q1 		$8K Sell
218
-73
-25% -$4.16K ﹤0.01% 899
2020
Q4 		$18K Sell
291
-79
-21% -$3.62K ﹤0.01% 789
2020
Q3 		$12K Buy
+370
New +$10.6K ﹤0.01% 810

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HM Payson & Co's STOK Position: Q1 2022 in Review

HM Payson & Co sold out of Stoke Therapeutics (STOK) in Q1 2022, closing a stake of 99 shares — an estimated $2K sold.

HM Payson & Co first reported a position in STOK in Q3 2020 and held it in 4 quarters. The position peaked at $18K in Q4 2020. 99 funds tracked by Wall St. Rank hold STOK as of Q1 2022.

  • HM Payson & Co reported no remaining Stoke Therapeutics position as of Q1 2022 after selling out during the quarter.
  • HM Payson & Co sold 99 Stoke Therapeutics shares in Q1 2022, an estimated $2K.
  • HM Payson & Co first reported a position in Stoke Therapeutics in Q3 2020 and held it in 4 quarters.
  • HM Payson & Co's Stoke Therapeutics position peaked at $18K in Q4 2020.
  • 99 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2022.

Based on HM Payson & Co's 13F filing for Q1 2022, filed 12 May 2022.